Top Medical Stocks To Buy Right Now

ConforMIS (NASDAQ:CFMS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. “

Several other research analysts also recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $4.00 price target on shares of ConforMIS in a research report on Wednesday, January 10th. JPMorgan Chase downgraded shares of ConforMIS from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Oppenheimer reiterated a “buy” rating on shares of ConforMIS in a report on Thursday, March 22nd. Cowen assumed coverage on shares of ConforMIS in a report on Wednesday, February 21st. They issued an “outperform” rating and a $4.00 price objective for the company. Finally, Canaccord Genuity upgraded shares of ConforMIS from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Tuesday, April 10th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. ConforMIS currently has an average rating of “Hold” and a consensus price target of $4.29.

Top Medical Stocks To Buy Right Now: First Mid-Illinois Bancshares, Inc.(FMBH)

Advisors’ Opinion:

Top Medical Stocks To Buy Right Now: Huntsman Corporation(HUN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Venator Materials PLC is a maker of titanium dioxide pigments and additives. The company is being spun out of Huntsman Corp. (NYSE: HUN) and plans to offer 22.7 million shares in an expected price range of $20 to $21, raising $465 million at an implied market cap of $2.18 billion. Underwriters include Citi, Goldman Sachs, BofA/Merrill Lynch, J.P. Morgan, Barclays, Deutsche Bank, UBS Investment Bank, RBC Capital Markets, Moelis & Company, HSBC Corp., Nomura Securities, SunTrust Robinson Humphrey, Academy Securities, and Commerzbank Capital. Shares are scheduled to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol VNTR.

  • [By Max Byerly]

    Cypress Capital Management LLC WY increased its position in Huntsman Corp (NYSE:HUN) by 175.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,460 shares of the basic materials company’s stock after acquiring an additional 11,130 shares during the period. Cypress Capital Management LLC WY’s holdings in Huntsman were worth $513,000 at the end of the most recent reporting period.

  • [By Lee Jackson]

    Huntsman Corp. (NYSE: HUN) had its executive chairman selling stock last week. Jon Huntsman parted with 600,000 shares, and the share priceranged from $17.25 to $17.27. The total for the trade was posted at $10 million.The company manufactures and sells differentiated organic and inorganic chemical products worldwide. The stock traded Friday at $18.10, so some left on that table as well.

Top Medical Stocks To Buy Right Now: SPDR Wells Fargo Preferred Stock ETF (PSK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI holds five other SSgA fixed income ETFs, including the SPDR Wells Fargo Preferred Stock ETF (NYSE: PSK). PSK is DWFI's largest holding at a weight of 25.2 percent. DWFI's second-largest holding is an allocation of almost 25 percent to the SPDR Nuveen Barclays Municipal Bond ETF (NYSE: TFI).

Top Medical Stocks To Buy Right Now: Tarena International, Inc.(TEDU)

Advisors’ Opinion:

  • [By Monica Gerson]

    Tarena International Inc(ADR) (NASDAQ: TEDU) is estimated to post a quarterly loss at $0.03 per share on revenue of $39.35 million.

    Ituran Location and Control Ltd. (US) (NASDAQ: ITRN) is projected to post earnings for the recent quarter.

  • [By Lisa Levin]

    Tarena International Inc(ADR) (NASDAQ: TEDU) shares dropped 23 percent to $14.24. Tarena International reported Q2 earnings of RMB$1.00 per share on sales of RMB$455.83 million. Nomura downgraded Tarena from Buy to Neutral.

Top Medical Stocks To Buy Right Now: Marathon Oil Corporation(MRO)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Marathon Oil Corp. (NYSE: MRO) which traded down 8.7% at $14.86. The stocks 52-week range is $9.65 to $19.28. Volume was about 108% of the daily average of around 11.32 million shares. The company had no specific news but was continuing to drop from falling crude prices.

  • [By Paul Ausick]

    Marathon Oil Corp. (NYSE: MRO) dropped about 1.1% Monday to post a new 52-week low of $11.40 after closing Friday at $11.53. The 52-week high is $19.28. Volume was about 40% lower than the daily average of about 13.7 million shares. The company had no specific news.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Marathon Oil (MRO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By WWW.THESTREET.COM]

    Cramer said he tried to buck this trend by investing in EOG Resources (EOG) and Marathon Oil (MRO) but was wrong on both counts. In the case of EOG, even having the best properties wasn’t enough to ward off the collapse in oil prices. Meanwhile, Marathon’s decision to spin off its refining business left it with no cushion to stem its losses.

Top Medical Stocks To Buy Right Now: Inovio Pharmaceuticals, Inc.(INO)

Advisors’ Opinion:

  • [By Keith Speights]

    A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.

  • [By William Patalon III]

    In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

  • [By Lisa Levin]

    Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were also up, gaining 24 percent to $8.84 following announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response.

Leave a Reply

Your email address will not be published. Required fields are marked *